LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
65.01
-0.13 (-0.20%)
At close: Apr 16, 2026, 4:00 PM EDT
65.01
0.00 (0.00%)
After-hours: Apr 16, 2026, 5:23 PM EDT
LivaNova Revenue
In the year 2025, LivaNova had annual revenue of $1.39B with 10.74% growth. LivaNova had revenue of $360.92M in the quarter ending December 31, 2025, with 12.16% growth.
Revenue (ttm)
$1.39B
Revenue Growth
+10.74%
P/S Ratio
2.56
Revenue / Employee
$420,622
Employees
3,300
Market Cap
3.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | 134.61M | 10.74% |
| Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
| Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
| Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
| Dec 31, 2021 | 1.04B | 101.13M | 10.82% |
| Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
| Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
| Dec 31, 2018 | 1.11B | 94.68M | 9.35% |
| Dec 31, 2017 | 1.01B | 47.42M | 4.91% |
| Dec 31, 2016 | 964.86M | 673.30M | 230.93% |
| Apr 24, 2015 | 291.56M | 9.54M | 3.38% |
| Apr 25, 2014 | 282.01M | 27.69M | 10.89% |
| Apr 26, 2013 | 254.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.44B |
| Integer Holdings | 1.85B |
| Haemonetics | 1.32B |
| Neogen | 870.56M |
| Alphatec Holdings | 764.16M |
| iRhythm Holdings | 747.14M |
| TransMedics Group | 605.49M |
| Glaukos | 507.44M |
LIVN News
- 22 days ago - LivaNova to Announce First-Quarter 2026 Results - Business Wire
- 4 weeks ago - LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea - Business Wire
- 7 weeks ago - LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance - Business Wire
- 3 months ago - LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results - Business Wire
- 4 months ago - LivaNova to Present at J.P. Morgan Healthcare Conference in January - Business Wire
- 4 months ago - LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting - Business Wire
- 4 months ago - LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea - Business Wire
- 5 months ago - LivaNova to Present at Piper Sandler Healthcare Conference in December - Business Wire